qtr-one adjusted non-gaap earnings per share $num-one.
qtr-one revenue rose 58 percent to $num-one billion.
for qtr-two year-six, company anticipates that non-gaap core revenue growth will be in mid-num-one percent range.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be in high-teens percent range.